Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919859 | 0.92 | CYP2C8 (0.62) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2139914 | 0.90 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2837517 | 0.87 | CYP3A4 (0.51) | CYP2C8CYP3A4KCNH2NR1I2CYP2C9 | |
| SCHEMBL12940351 | 0.87 | CYP3A4 (0.51) | CYP2C8CYP3A4KCNH2NR1I2CYP2C9 | |
| SCHEMBL10242360 | 0.85 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL10240833 | 0.84 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2CYP2C9 | |
| SCHEMBL1917995 | 0.84 | CYP2C8 (0.54) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL142568 | 0.84 | CYP2C8 (0.72) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL1918922 | 0.84 | CYP2C8 (0.53) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL143697 | 0.84 | CYP2C8 (0.55) | CYP2C8CYP3A4KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885CYP3A4 299/4885KCNH2 3814/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885CYP3A4 299/4885KCNH2 3814/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885CYP3A4 299/4885KCNH2 3814/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885CYP3A4 299/4885KCNH2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.